Darovasertib data are promised for the last week of March.
ApexOnco Front Page
Recent articles
Just like other oral SERDs, filing is restricted to the ESR1-mutant population.
Another KRAS G12D inhibitor hits the clinic, while Zai Lab hopes to banish the spectre of Rova-T.
Five years after Affimed switched to NK cell engagers investors will see the fruits of a potentially registrational trial.
The group’s $4.1bn swoop for RayzeBio follows big deals from Novartis and Lilly.
As the biotech markets turned bullish the sector’s ups and downs continued.
Acquiring Gracell at an 86% premium raises hopes that the biotech markets are bottoming out after a turbulent two years.
Imbruvica faces challenges on multiple fronts.